Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Grow...(cholesterol) HDL (good cholesterol) and ...),Health

single pill.

* HUMIRA(R) Indications Approved

o Psoriasis -- Abbott received FDA approval for HUMIRA to treat

moderate to severe plaque psoriasis. In clinical trials, nearly

75 percent of patients treated with HUMIRA achieved a

75 percent reduction in psoriasis symptoms. Psoriasis affects

125 million people worldwide.

o Juvenile Rheumatoid Arthritis (JRA) -- Also in the quarter,

Abbott received FDA approval for HUMIRA to treat moderate to

severely active polyarticular juvenile idiopathic arthritis,

commonly referred to as JRA in the United States.

o RA in Japan -- In April, Abbott also received Japanese approval

for HUMIRA to treat RA.

* TAP Joint Venture to Conclude -- In March, Abbott and Takeda

Pharmaceutical announced an agreement to conclude their 31-year TAP

joint venture. Abbott and Takeda will evenly split the value and

assets of the joint venture, with Abbott receiving full ownership of

the oncology treatment, Lupron, including its U.S. commercial

organization, as well as future cash payments from Takeda over the

next five years. The transaction is expected to close in the second

quarter of 2008.

* Data Presented at the American College of Cardiology (ACC)

Conference

o TriLipix(R) -- Abbott presented Phase III data on TriLipix,

formerly known as ABT-335, Abbott's next-generation fenofibrate

therapy. Data demonstrated that TriLipix, in combination with

statin therapy, is safe and effective at improving three key

lipids, HDL, LDL and triglycerides.

o Xience(TM) V -- Abbott also presented
'/>"/>